Alex Kim, MA
Chief Executive Officer
Alex Kim joined Elevar Therapeutics in May of 2007. In December of 2007, he was elected to the Board of Directors and became CEO in 2019. Alex has 30 years’ experience in the pharmaceutical industry at MacroMed, Inc. (formerly Protherics, Plc, now BTG, Plc); Expression Genetics, Inc.; VivoRx, Inc. (Abraxis, acquired by Cellgene); and Theratech (now Watson Pharmaceuticals). Alex’s experience at these companies includes executive management, business development, product and technology licensing, strategic planning, fund raising and M&A activity. He has closed financing deals in Europe, Asia and the US.
Alex received his master’s degree in international business from Sophia University (Sang Ji) in Tokyo, Japan and Bachelor’s Degree in Political Science with a Minor in Economics from the University of Utah. He is a member of the Board of Directors of Co-D Therapeutics and Immunomic Therapeutics.
Kate McKinley, MBA
Chief Commercial Officer
Kate McKinley joined Elevar Therapeutics’ Executive Team in 2019, to design and lead the global commercialization strategy for the pipeline and lead the business development organization. Kate’s team includes, global commercial, corporate communications, business development and alliance management. Prior to joining Elevar Therapeutics, Kate led the Marketing organization and served as a key member of the Operating Committee, for Dendreon Pharmaceuticals, a company focused on immunotherapy. Kate worked at Abbott Laboratories and the biopharmaceutical spinoff, AbbVie, for 17 years in all aspects of commercialization, including sales leadership and market access, and spent 3 years leading the Urology, Oncology and Gynecology US sales organizations.
Kate is a summa cum laude graduate of The University of Tulsa. She holds an M.B.A. from the university’s Collins College of Business and a Bachelor of Science in Business Administration with degrees in Marketing, Management and Psychology.
Mark S. Gelder, M.D.
Chief Medical Officer
Dr. Mark Gelder joined Elevar in 2020 as vice president of medical affairs and within the same year was promoted to chief medical officer where he has been building and leading Elevar’s global medical organization, setting the strategy for development programs from clinical trials through regulatory filings, new product launches and lifecycle opportunities. In his role as chief medical officer, Mark oversees the Company’s clinical development, medical affairs, regulatory affairs, and preclinical teams.
Mark brings more than 35 years of clinical development, medical affairs and medical marketing experience including 17 years of global medical affairs experience leading therapeutic oncology programs for companies like Pfizer, Wyeth and Bayer, where he was involved in the approval and launch of several cancer therapeutics. Mark has led successful global trials, launch plans and Phase I-Phase IV studies for several emerging oncology organizations and has been instrumental in the approval and launch of numerous oncology products.
Mark earned his medical doctorate from the University of Virginia School of Medicine and completed his residency training internal medicine and obstetrics and gynecology followed by a gynecologic oncology fellowship. He is a Fellow of the American College of Physicians and the American College of Obstetrics and Gynecology and has extensive clinical experience in both the academic and private practice settings.
Prior to joining the industry, he was an investigator in multiple clinical trials and has authored numerous scientific papers in the areas of women’s health and oncology.